2021 Vol.2 Sept.No4

• Title: Effect of commitment therapy intervention program on nursing care of patients with cardiovascular and cerebrovascular complicati
• Name: Takemoto Eiji,Family Tanaka Riko
• Company: (Tokyo Senkaku University,katsushika 125-0062,Japan)
• Abstract:

  Objective: To understand the anxiety, depression and quality of life of patients with cardiovascular and cerebrovascular complications, and to improve the psychological resilience, self-esteem and adaptability of patients with cardiovascular and cerebrovascular complications by using the intervention program of acceptance commitment therapy. Methods: From March 2018 to July 2018, a total of 196 patients with cardiovascular and cerebrovascular complications in our hospital for 5 months were selected as the research objects, and randomly divided into the control group and the observation group with 98 samples each. The control group received routine clinical nursing intervention, while the observation group received nursing intervention guided by acceptance and commitment therapy on the basis of routine clinical nursing. Results: The psychological resilience, adaptive level and self-care ability of patients were evaluated before and after 5 months of intervention. The incidence of cardiovascular and cerebrovascular complications, anxiety and depression in the observation group were lower, and the quality of life was higher. Conclusion: Applying the intervention program of acceptance and commitment therapy to the nursing of patients with cardiovascular and cerebrovascular complications can significantly improve their self-esteem, alleviate their psychological barriers and promote their postoperative social adaptation.

  
  

• Keyword: Acceptance therapy; Patients with cardiovascular and cerebrovascular complications; Anxiety state; Depressed state; Quality of life
• DOI: 10.12250/jpcarme2021020434
• Citation form: Takemoto Eiji,Family Tanaka Riko.Effect of commitment therapy intervention program on nursing care of patients with cardiovascular and cerebrovascular complications.2020, vol. 3, 6-11.

[1]Harding A H, Darnton A, Osman J. Cardiovascular disease mortality among British asbestos workers (1971-2005)[J].Occupational and environmental medicine,2012,69(6):417-421.

[2]Robert C. Homocysteine, B vitamins, and the risk of cardiovascular disease.[J].Clinical chemistry,2011,57(8):1201-1202.

[3]De, Mello, Walmor, et al. Local Renin Angiotensin Aldosterone Systems and Cardiovascular Diseases[J]. The Medical Clinics of North America, 2017, 101(1):117-127.

[4]Erfurth EM, Hagmar L. Cerebrovascular disease in patients with pituitary tumors.[J].Trends in Endocrinology and Metabolism: TEM,2005,16(7):334-342.

[5]Richard H S. Moving vessel wall research beyond the plaque: basilar artery dilation as a window to systemic cardiovascular events.[J].Arteriosclerosis, thrombosis, and vascular biology,2013,33(9):2051-2052.

[6]Luan J, Zhai, G. Targeted Drug Delivery for Cardiovascular and Cerebrovascular Diseases[J].Current drug targets-The International journal for timely in-depth reviews on drug targets,2016,17(4):467-474.

[7]So E S. Cardiovascular disease risk factors associated with depression among Korean adults with coronary artery disease and cerebrovascular disease[J].Asia-Pacific psychiatry,2015,7(2):173-181.

[8]Webb S M, Mo D, Lamberts S W, et.al. Metabolic, cardiovascular, and cerebrovascular outcomes in growth hormone-deficient subjects with previous cushing's disease or non-functioning pituitary adenoma.[J].The Journal of Clinical Endocrinology and Metabolism,2010,95(2):630-638.

[9]Moussouttas M, Papamitsakis N. Combination antiplatelet agents in ischemic cerebrovascular disease.[J].The Mount Sinai journal of medicine,2005,72(1):16-22.